Form 4: Sonoma Pharmaceuticals CFO Jerome Dvonch Reports Stock Award and Disposal

Jerome Dvonch, CFO of Sonoma Pharmaceuticals, reports acquiring 53,586 shares and disposing of 84,595 shares of common stock on June 20, 2024.

Summary

• On June 20, 2024, Jerome Dvonch, the Chief Financial Officer of Sonoma Pharmaceuticals, reported transactions involving the company's common stock.
• Mr. Dvonch acquired 53,586 shares of common stock.
• He also disposed of 84,595 shares.
• Following these transactions, Mr. Dvonch beneficially owns 84,595 shares of Sonoma Pharmaceuticals.
• The shares acquired were awarded as Restricted Stock Units for services performed as part of the company's annual bonus compensation to executives and vested fully on the grant date.

Sentiment

Score: 5

Explanation: The document itself is neutral, simply reporting transactions. The impact on sentiment depends on how investors interpret the CFO's actions.

Positives

• The acquisition of shares by the CFO could be seen as a positive signal, indicating confidence in the company's future performance.

Negatives

• The disposal of 84,595 shares by the CFO could be interpreted negatively by some investors.

Risks

• The document does not explicitly mention any risks.
• However, investor sentiment could be negatively impacted by the disposal of shares by a key executive.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders.

Stakeholder Impact

• Shareholders may react to the reported stock transactions by the CFO.
• The transactions could influence investor confidence in the company.

Key Dates

Keywords

Sonoma Pharmaceuticals, Jerome Dvonch, CFO, stock, acquisition, disposal, Form 4, Restricted Stock Units, SNOA